ArticleJournal of experimental & clinical cancer research : CR2022

Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial.

Carminia Maria Della Corte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.